Welcome to our dedicated page for Takeda Pharm news (Ticker: TAK), a resource for investors and traders seeking the latest updates and insights on Takeda Pharm stock.
The TAK news page on Stock Titan aggregates company-specific coverage for Takeda Pharmaceutical Company Limited American Depositary Shares (NYSE: TAK). Takeda’s own disclosures describe it as a values-based, R&D-driven biopharmaceutical company headquartered in Japan, with core therapeutic and business areas in gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Because of this broad focus and active pipeline, Takeda generates frequent news across clinical, regulatory, partnership and financial topics.
Recent press releases highlight late-stage clinical data and regulatory plans for several key programs. In neuroscience, Takeda has presented Phase 3 results for oveporexton (TAK-861), an investigational oral orexin receptor 2 agonist for narcolepsy type 1, showing statistically significant improvements in excessive daytime sleepiness, cataplexy and quality-of-life measures versus placebo. In immunology and dermatology, the company has reported pivotal Phase 3 data for zasocitinib (TAK-279), an investigational highly selective oral TYK2 inhibitor in moderate-to-severe plaque psoriasis, with studies meeting all primary and ranked secondary endpoints.
Takeda news also covers hematology and rare disease developments. Together with Protagonist Therapeutics, the company has released Phase 3 VERIFY and long-term THRIVE data for rusfertide, an investigational hepcidin mimetic for polycythemia vera, demonstrating durable hematocrit control, reduced phlebotomy requirements and maintained patient-reported outcome improvements. In nephrology, Takeda has shared Phase 1b data for mezagitamab (TAK-079) in primary IgA nephropathy, showing stable kidney function and sustained reductions in proteinuria and Gd-IgA1 levels up to 18 months after the last dose.
In vaccines, Takeda has announced seven-year Phase 3 TIDES trial data for its dengue vaccine QDENGA (TAK-003), reinforcing sustained protection against virologically confirmed dengue and dengue-related hospitalizations and supporting a two-dose regimen. Corporate and pipeline news includes strategic oncology collaborations, such as the global partnership with Innovent Biologics for late-stage assets IBI363 and IBI343, and financial updates on revenue trends, generic erosion impacts and revised full-year forecasts.
Investors and followers of TAK can use this news feed to track Takeda’s clinical milestones, regulatory filings, strategic alliances, portfolio prioritization decisions and IFRS-based financial disclosures as they are reported in press releases and SEC Form 6-K submissions.
Takeda Pharmaceutical Company has agreed to divest a non-core portfolio of prescription pharmaceutical products in China to Hasten Biopharmaceutic Co., Ltd. for $322 million. This portfolio, which generated approximately $109.5 million in sales during FY2019, includes cardiovascular products like Ebrantil. The divestiture aligns with Takeda's strategy to focus on core therapeutic areas such as Gastroenterology and Oncology. Proceeds will be used to reduce debt and support long-term growth, with over 15 product approvals planned in China over the next five years.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) announced FDA approval for the supplemental New Drug Application (sNDA) of ICLUSIG® (ponatinib) for adults with chronic-phase chronic myeloid leukemia (CML) who are resistant or intolerant to at least two prior kinase inhibitors. The updated regimen features a starting dose of 45 mg, reducing to 15 mg upon achieving ≤1% BCR-ABL1IS. The approval is based on data from the OPTIC and PACE trials. The revised label is expected to optimize treatment for patients with resistant CML, providing significant clinical benefits.
Prime Therapeutics has secured an agreement with Takeda Pharmaceuticals for its hemophilia A treatment, ADVATE. This collaboration aims to evaluate clinical outcomes and costs associated with hemophilia A treatments, which have become increasingly expensive. The agreement introduces a health plan remuneration model linked to quantifiable medical costs from ineffective treatments under a total cost of care framework. Hemophilia A affects around 80% of the 18,000 people living with the disorder in the U.S., presenting an opportunity for improved patient and cost outcomes.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) announced that the FDA has accepted its New Drug Application for TAK-721, a treatment for eosinophilic esophagitis (EoE), granting it Priority Review. If approved, TAK-721 will be the first FDA-approved therapy for EoE. The product had previously received Breakthrough Therapy and Orphan Drug designations. The NDA filing is based on successful Phase 3 trials demonstrating its safety and efficacy. EoE affects approximately 1 in 2,000 people in the U.S., leading to significant quality of life impacts due to related symptoms.
Takeda Pharmaceutical Company Limited (TAK) has completed the sale of a portfolio of 18 pharmaceutical and OTC products to Celltrion Inc. for $278 million, including milestone payments. This divestment, part of Takeda's strategy to focus on core areas, is expected to aid in reducing debt and accelerating deleveraging to achieve a net debt/adjusted EBITDA target of 2x by FY 2023. The sale comes after Takeda exceeded its $10 billion non-core asset divestiture target, totaling ~$11.3 billion in agreements since January 2019.
On November 11, 2020, Takeda announced a strategic partnership with OrigiMed to create a genomic-based precision medicine platform. This collaboration aims to enhance R&D and commercialization of innovative medicines in China, addressing unmet medical needs. Takeda plans to introduce over 15 innovative drugs to the Chinese market within five years, benefiting approximately 10 million patients. OrigiMed will leverage its genomic datasets and advanced sequencing technology to support these developments.
Seqster PDM Inc. and Takeda Pharmaceutical Company Limited have extended their partnership to enhance patient outcomes by leveraging Seqster's healthcare technology. The collaboration will provide Takeda with immediate access to Seqster's secure platform, which integrates electronic health records, genomic data, and wearable information. This will facilitate real-time data visualization, improving patient engagement and compliance during clinical trials. The implementation will enable Takeda to activate 12 use cases across its business rapidly, aiming to enhance clinical development and patient services.
Takeda Pharmaceuticals reported Q2 FY2020 results, showing resilience amidst COVID-19 challenges. Revenue reached JPY 1,590.8 billion, reflecting a 0.5% underlying growth despite a 4.2% decline. Operating profit surged by 97.7% to JPY 215.6 billion, with net profit up 15.8% to JPY 86.5 billion. The company confirmed its full-year guidance, upgrading forecasts for free cash flow and earnings per share. Takeda's ongoing divestitures, exceeding $11 billion since January 2019, are strengthening its balance sheet and reducing debt, with an aim to achieve a net debt/EBITDA ratio of 2x by FY2021-FY2023.
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) presented four abstracts at the Thrombosis and Hemostasis Summit of North America, focusing on advancements in personalized care for bleeding disorders. Key studies include evaluating rurioctocog alfa pegol in hemophilia A and B, implementing a Goal Attainment Scaling instrument for hemophilia, and insights into population pharmacokinetics of recombinant von Willebrand factor. These presentations emphasize personalized treatment strategies aimed at enhancing patient care in hemophilia and von Willebrand's disease.
Takeda Pharmaceutical Company and Arrowhead Pharmaceuticals have formed a collaboration to co-develop ARO-AAT, an investigational RNA interference therapy for alpha-1 antitrypsin-associated liver disease (AATLD). Under a profit-sharing agreement, they will share U.S. commercialization efforts 50/50, while Takeda will lead global commercialization outside the U.S. Arrowhead receives a $300 million upfront payment and may earn up to $740 million in milestone payments. This partnership aims to address the significant unmet medical need for AATLD, a serious condition with no current approved therapies.